157 related articles for article (PubMed ID: 1923504)
1. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
Casey G; Lo-Hsueh M; Lopez ME; Vogelstein B; Stanbridge EJ
Oncogene; 1991 Oct; 6(10):1791-7. PubMed ID: 1923504
[TBL] [Abstract][Full Text] [Related]
2. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM
Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297
[TBL] [Abstract][Full Text] [Related]
3. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs WB; Carter BS; Ewing CM
Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816
[TBL] [Abstract][Full Text] [Related]
5. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate.
Chen YM; Chen PL; Arnaiz N; Goodrich D; Lee WH
Oncogene; 1991 Oct; 6(10):1799-805. PubMed ID: 1923505
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M
Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785
[TBL] [Abstract][Full Text] [Related]
7. Distinct promoter usage of mdm2 gene in human breast cancer.
Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S
Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
Li H; Weinstein IB
Cancer Res; 2006 Dec; 66(23):11399-408. PubMed ID: 17145886
[TBL] [Abstract][Full Text] [Related]
9. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein.
Cajot JF; Anderson MJ; Lehman TA; Shapiro H; Briggs AA; Stanbridge EJ
Cancer Res; 1992 Dec; 52(24):6956-60. PubMed ID: 1458487
[TBL] [Abstract][Full Text] [Related]
10. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line].
Wang H; Lai B; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947
[TBL] [Abstract][Full Text] [Related]
11. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
12. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
Kang H; Mansel RE; Jiang WG
Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.
Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P
Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059
[TBL] [Abstract][Full Text] [Related]
14. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
15. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
16. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.
Vinyals A; Peinado MA; Gonzalez-Garrigues M; Monzó M; Bonfil RD; Fabra A
Gene Ther; 1999 Jan; 6(1):22-33. PubMed ID: 10341872
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells.
Wang NP; To H; Lee WH; Lee EY
Oncogene; 1993 Feb; 8(2):279-88. PubMed ID: 8426737
[TBL] [Abstract][Full Text] [Related]
19. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ
Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
